TerminatedPhase 1NCT04963413

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Florida
Principal Investigator
Ashley Ghiaseddin, MD
University of Florida
Intervention
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF(biological)
Enrollment
6 enrolled
Eligibility
18-90 years · All sexes
Timeline
20222023

Study locations (1)

Collaborators

Immunomic Therapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04963413 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials